NovaBay Pharmaceuticals(NYSEMKT:NBY) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $4.077M. Analysts estimated a revenue of $4.230M. The revenues were -3.62% below the estimates. Earnings per share were $-0.13. The reported EPS was below estimates by -85.71%. Analysts had estimated an EPS of $-0.07.
NovaBay Pharmaceuticals (NBY) remained unchanged at the close of Friday session. Even as the volume increased to 13,091 ,the shares failed to make any impression and ended at 0 points or 0.00% at $3.8. The trading session commenced at $3.85 and the stock hit a high of $3.85 and touched $3.7 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $5.29 and the 52-week low is $1.9. The company has a market cap of $58 M and has approximately 1,52,88,175 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Aug 21, 2015, Ramin Najafi (CEO) purchased 12,000 shares at $0.47 per share price.Also, On Mar 5, 2015, Mark M Sieczkarek (director) purchased 166,666 shares at $0.60 per share price.On Mar 5, 2015, Pharma (singapore) Pte Pioneer (10% owner) purchased 2,590,000 shares at $0.60 per share price, according to the Form-4 filing with the securities and exchange commission.
NovaBay Pharmaceuticals Inc. (NovaBay) is a biopharmaceutical company. The Company operates through four segments: dermatology ophthalmology urology and wound care. The dermatology segment includes NovaBay’s business around the dermatology area including the collaboration with Galderma and their impetigo clinical trial. The dermatology product includes CelleRx a cleansing solution for post laser resurfacing chemical peels and other cosmetic surgery procedures. The ophthalmology segment includes Avenova and its clinical trial on ophthalmology which it was conducting on its own. The ophthalmology segment also includes the i-Case product which is in development phases. The urology segment includes its urinary catheter encrustation and blockage (UCBE) trials. NovaBay completed Phase II clinical study of auriclosene to reduce UCBE. The wound care segment includes the business of NeutroPhase product. Its products under development stage include Aganocide Compounds.